- Previous Rank224
- Revenues ($M)$15,281.0
- Revenue Percent Change17.5%
- Profits ($M)$4,046.0
- Profits Percent Change37.6%
- Assets ($M)$35,480.0
- Employees8,852
The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multiple myeloma, inflammatory diseases, and various forms of cancer.
Looking for leads, investment insights, or competitive intelligence?Buy Now
Company Info
| CEO | Mark J. Alles |
| CEO Title | Chairman & Chief Executive Officer |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | Summit, N.J. |
| Website | http://www.celgene.com |
| Years on Fortune 500 List | 8 |
| Employees | 8,852 |
Celgene Rank History
placeholder
Key Financials (Last Fiscal Year)
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $15,281.0 | 17.5% |
| Profits ($M) | $4,046.0 | 37.6% |
| Assets ($M) | $35,480.0 | - |
| Total Stockholder Equity ($M) | $6,161.0 | - |
Profit Ratios
| Profit as % of Revenues | 26.5% |
| Profits as % of Assets | 11.4% |
| Profits as % of Stockholder Equity | 65.7% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 5.51 |
| EPS % Change (from 2017) | 51.4% |
| EPS % Change (5 year annual rate) | 26.7% |
| EPS % Change (10 year annual rate) | - |
Total Return
| Total Return to Investors (2018) | -38.6% |
| Total Return to Investors (5 year, annualized) | -5.4% |
| Total Return to Investors (10 year, annualized) | 8.8% |
